Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Coronary Artery Disease HELP
Based on 29,177 articles since 2006
|||| 10 

These are the 29177 published articles about Coronary Artery Disease that originated from Worldwide during 2006-2015.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
1 Guideline [SICI-GISE position paper on standards and guidelines for diagnostic and catheterization laboratories]. 2015

Piccaluga, Emanuela / Marchese, Alfredo / Varbella, Ferdinando / Sardella, Gennaro / Danzi, Gian Battista / Salvi, Alessandro / Cremonesi, Alberto / Merelli, Antonella / Ciarma, Lorenzo / Magro, Beatrice / Bedogni, Francesco / Anonymous3290867. ·Cardiologia 1-Emodinamica, A.O. Ospedale Niguarda Ca' Granda, Milano. · U.O. Cardiologia Interventistica, Anthea Hospital, GVM Care & Research, Bari. · Dipartimento di Cardiologia, Ospedale degli Infermi, Rivoli (TO). · Dipartimento di Scienze Cardiovascolari, Respiratorie, Nefrologiche, Anestesiologiche e Geriatriche, Sapienza Università di Roma, Roma. · U.O. Cardiologia, Ospedale Santa Corona, Pietra Ligure (SV). · Emodinamica Diagnostica e Interventistica, Azienda Ospedaliero-Universitaria "Ospedali Riuniti", Trieste. · Laboratorio di Cardio-Angiologia Diagnostica ed Interventistica, Maria Cecilia Hospital, GVM Care & Research, Cotignola (RA). · U.O. Cardiologia 2, Azienda Ospedaliero-Universitaria Pisana, Pisa. · U.O. Emodinamica, Policlinico S. Orsola-Malpighi, Bologna. · UOSD Diagnostica ed Interventistica Cardiovascolare Endoluminale, Ospedale Civile "S. Maria della Misericordia", ULSS 18, Rovigo. · Dipartimento di Cardiologia, IRCCS Policlinico San Donato, San Donato Milanese (MI). · ·G Ital Cardiol (Rome) · Pubmed #26444219.

ABSTRACT: In the last few years, the activity of cath labs has undergone some notable changes, at present largely focusing on diagnosis and invasive therapy of a broad spectrum of cardiovascular diseases. Technological and pharmacological advances have allowed for procedures to be performed in patients who are increasingly complex, and cath labs have become the preferred venue for endovascular treatment of coronary artery disease, in particular acute coronary syndrome, as well as the treatment of structural heart disease and peripheral vascular disease. This position paper is an update of the 1996 and 2008 versions, given the present level of experience and the situation in Italy. It aims to provide the quality standards required to maintain adequate conditions of know-how and safety, as well as the structural and organizational requirements that are fundamental to obtain the best possible use of human and technological resources. Position papers should be a stimulus and guide for operators in the field as well as for those who govern health policies. This should allow for an improved and more rational allocation of cath labs in Italy, based on the real need for procedures and an optimal distribution and organization of the cardiovascular emergency networks while respecting the minimum standards of care.

2 Guideline [Position paper of the Italian Society of Invasive Cardiology (SICI-GISE) on indications for coronary angiography in patients with stable angina]. 2015

Marchese, Alfredo / Rossini, Roberta / Basile, Marco / Bedogni, Francesco / Danzi, Gian Battista / Musumeci, Giuseppe / Paradies, Valeria / Piccaluga, Emanuela / Sardella, Gennaro / Varbella, Ferdinando / Giordano, Arturo / Berti, Sergio / Anonymous3280867. ·U.O.C. Cardiologia Interventistica, Anthea Hospital, GVM Care & Research, Bari. · Dipartimento Cardiovascolare, A.O. Papa Giovanni XXIII, Bergamo. · Dipartimento di Cardiologia, IRCCS Policlinico San Donato, San Donato Milanese (MI). · U.O. Cardiologia, Ospedale Santa Corona, Pietra Ligure (SV). · Cardiologia 1-Emodinamica, A.O. Ospedale Niguarda Ca' Granda, Milano. · Dipartimento di Scienze Cardiovascolari, Respiratorie, Nefrologiche, Anestesiologiche e Geriatriche, Sapienza Università di Roma, Roma. · Dipartimento di Cardiologia, Ospedale degli Infermi, Rivoli (TO). · U.O.C. Cardiologia Interventistica, Clinica Pineta Grande, Castel Volturno (CE). · U.O. Cardiologia Diagnostica ed Interventistica, Fondazione Toscana "Gabriele Monasterio", Ospedale del Cuore, Massa. · ·G Ital Cardiol (Rome) · Pubmed #26444218.

ABSTRACT: Available data suggest a steep increase in stable coronary artery disease with age. Its prevalence reaches a peak of almost 12-14% in men aged 65-84 years with an annual mortality ranging from 1.2% to 2.4%. The diagnosis of stable angina is primarily based on history and therefore relies on clinical judgment. In addition, its diagnosis can be extremely challenging because of the frequent transition from unstable to stable angina. Current European guidelines on the management of stable coronary artery disease give increased importance to the pre-test probability, which strongly affects the diagnostic algorithms. Imaging techniques play a greater role in the diagnosis of stable angina than in the past. Conversely, despite recent advances in technology and in the physiological assessment of coronary stenosis, an ever decreasing relevance is conferred to coronary angiography. Another difficult and controversial issue relates to the prognostic benefit of myocardial revascularization. The aim of this position paper is to review the most relevant clinical aspects of the European guidelines on the management of stable coronary artery disease.

3 Guideline [Update on Current Care Guidelines. Current Care Guideline: Stable Coronary Artery Disease]. 2015

Porela, Pekka / Mäntylä, Pirjo / Blek-Vehkaluoto, Mari / Ilveskoski, Erkki / Juvonen, Tatu / Kujanpää, Tero / Loimaala, Antti / Meinander, Tuula / Mäenpää, Eliisa / Romppanen, Hannu / Saraste, Antti / Tierala, Ja Ilkka / Anonymous2050811. · ·Duodecim · Pubmed #26237876.

ABSTRACT: This guideline covers coronary heart disease symptoms, diagnosis and treatment. Stable coronary heart disease refers to a disease in, which patients have stable symptoms and evidence of ischemia or significant stenosis of coronary artery. Diagnosis is based on medical history and exercise test, which is the primary diagnostic test. Coronary angiography is in selected cases necessary to confirm the diagnosis and assess invasive treatment. Pharmacotherapy aims to improve the survival of the patient, relieve symptoms and improve quality of life. The guideline also deals with invasive treatment either with PCI or CABG.

4 Guideline Perspectives on the 2014 ESC/EACTS Guidelines on Myocardial Revascularization : Fifty Years of Revascularization: Where Are We and Where Are We Heading? 2015

Costa, Francesco / Ariotti, Sara / Valgimigli, Marco / Kolh, Philippe / Windecker, Stephan / Anonymous1240989. ·Thoraxcenter, Erasmus Medical Center, 3015 CE, Rotterdam, The Netherlands. · ·J Cardiovasc Transl Res · Pubmed #25986910.

ABSTRACT: The joint European Society of Cardiology and European Association of Cardio-Thoracic Surgery (ESC/EACTS) guidelines on myocardial revascularization collect and summarize the evidence regarding decision-making, diagnostics, and therapeutics in various clinical scenarios of coronary artery disease, including elective, urgent, and emergency settings. The 2014 document updates and extends the effort started in 2010, year of the first edition of these guidelines. Importantly, this latest edition provides a systematic review of all randomized clinical trials performed since 1980, comparing different strategies of myocardial revascularization, including coronary artery bypass graft (CABG), balloon angioplasty, percutaneous coronary intervention (PCI) with bare-metal stents (BMS) and first- and second-generation drug-eluting stents (DES). This review aims to highlight the most relevant novelties introduced by the 2014 edition of the ESC/EACTS myocardial revascularization guidelines as compared with the previous edition and to describe similarities and differences with the American societies' guidelines.

5 Guideline Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. 2015

Rosendorff, Clive / Lackland, Daniel T / Allison, Matthew / Aronow, Wilbert S / Black, Henry R / Blumenthal, Roger S / Cannon, Christopher P / de Lemos, James A / Elliott, William J / Findeiss, Laura / Gersh, Bernard J / Gore, Joel M / Levy, Daniel / Long, Janet B / O'Connor, Christopher M / O'Gara, Patrick T / Ogedegbe, Gbenga / Oparil, Suzanne / White, William B / Anonymous3850808. · ·Circulation · Pubmed #25829340.

ABSTRACT: -- No abstract --

6 Guideline Secondary prevention after coronary artery bypass graft surgery: a scientific statement from the American Heart Association. 2015

Kulik, Alexander / Ruel, Marc / Jneid, Hani / Ferguson, T Bruce / Hiratzka, Loren F / Ikonomidis, John S / Lopez-Jimenez, Francisco / McNallan, Sheila M / Patel, Mahesh / Roger, Véronique L / Sellke, Frank W / Sica, Domenic A / Zimmerman, Lani / Anonymous7180805. · ·Circulation · Pubmed #25679302.

ABSTRACT: -- No abstract --

7 Guideline 2014 Korean guidelines for appropriate utilization of cardiovascular magnetic resonance imaging: a joint report of the Korean Society of Cardiology and the Korean Society of Radiology. 2014

Yoon, Yeonyee E / Hong, Yoo Jin / Kim, Hyung-Kwan / Kim, Jeong A / Na, Jin Oh / Yang, Dong Hyun / Kim, Young Jin / Choi, Eui-Young / The Korean Society of Cardiology and the Korean Society of Radiology, ?. ·Department of Cardiology, Cardiovascular Center, Seoul National University Bundang Hospital, Seongnam 463-707, Korea. · Department of Radiology, Severance Hospital, Yonsei University College of Medicine, Seoul 120-752, Korea. · Division of Cardiology, Department of Internal Medicine, Cardiovascular Center, Seoul National University College of Medicine, Seoul National University Hospital, Seoul 110-744, Korea. · Department of Radiology, Ilsan Paik Hospital, Inje University College of Medicine, Goyang 411-706, Korea. · Cardiovascular Center, Korea University Guro Hospital, Korea University College of Medicine, Seoul 152-703, Korea. · Department of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul 138-736, Korea. · Division of Cardiology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul 135-720, Korea. · ·Korean J Radiol · Pubmed #25469078.

ABSTRACT: Cardiac magnetic resonance (CMR) imaging is now widely used in several fields of cardiovascular disease assessment due to recent technical developments. CMR can give physicians information that cannot be found with other imaging modalities. However, there is no guideline which is suitable for Korean people for the use of CMR. Therefore, we have prepared a Korean guideline for the appropriate utilization of CMR to guide Korean physicians, imaging specialists, medical associates and patients to improve the overall medical system performances. By addressing CMR usage and creating these guidelines we hope to contribute towards the promotion of public health. This guideline is a joint report of the Korean Society of Cardiology and the Korean Society of Radiology.

8 Guideline [Comments on the 2013 ESC/EASD guidelines on diabetes, prediabetes and cardiovascular diseases]. 2014

Motz, W / Kerner, W / Dörr, R / Anonymous1410798 / Anonymous1420798. ·Herz- und Diabeteszentrum Mecklenburg-Vorpommern, Klinikum Karlsburg, Klinikgruppe Dr. Guth GmbH & Co. KG, Greifswalder Str. 11, 17495, Karlsburg, Deutschland, motz@drguth.de. · ·Herz · Pubmed #25416683.

ABSTRACT: Patients with type 2 diabetes mellitus have an increased cardiovascular risk compared with non-diabetics. The new guidelines provide physicians with orientation with respect to disorders in glucose metabolism and the risk of occurrence of cardiovascular diseases. An HBA1c level in the range of 6-8% is currently recommended, depending on cardiovascular comorbidities: in young diabetics 6% is recommended to avoid hypoglycemia and in older individuals with cardiovascular complications 8%. The target blood pressure given in the new guidelines is <140/85 mmHg. The guidelines still recommend bypass surgery instead of percutaneous coronary intervention (PCI) for diabetics; however, this recommendation is based on studies that do not reflect current practice and is disputable. Diagnostic measures and therapy of cardiac failure and arrhythmic disorders in the guidelines do not essentially differ between patients with and without diabetes, basically due to a lack of studies.

9 Guideline Guideline for stable coronary artery disease. 2014

Cesar, L A / Ferreira, J F / Armaganijan, D / Gowdak, L H / Mansur, A P / Bodanese, L C / Sposito, A / Sousa, A C / Chaves, A J / Markman, B / Caramelli, B / Vianna, C B / Oliveira, C C / Meneghetti, C / Albuquerque, D C / Stefanini, E / Nagib, E / Pinto, I M F / Castro, I / Saad, J A / Schneider, J C / Tsutsui, J M / Carneiro, J K R / Torres, K / Piegas, L S / Dallan, L A / Lisboa, L A F / Sampaio, M F / Moretti, M A / Lopes, N H / Coelho, O R / Lemos, P / Santos, R D / Botelho, R / Staico, R / Meneghello, R / Montenegro, S T / Vaz, V D / Anonymous3050796. · ·Arq Bras Cardiol · Pubmed #25410086.

ABSTRACT: -- No abstract --

10 Guideline [ESC/EACTS guidelines on myocardial revascularization : Amendments 2014]. 2014

Nef, H / Renker, M / Hamm, C W / Anonymous1370798 / Anonymous1380798. ·Medizinische Klinik I, Kardiologie und Angiologie, Universitätsklinikum Gießen, Klinikstr. 33, 35392, Gießen, Deutschland, holger.nef@me.com. · ·Herz · Pubmed #25406330.

ABSTRACT: One of the most important treatment principles in interventional cardiology relies on myocardial revascularization by percutaneous coronary intervention (PCI) or surgical placement of coronary artery bypass grafts (CABG). However, in order to apply these principles effectively, it is important to identify patients who require revascularization. Consequently, the appropriate method has to be selected to effectively restore blood flow. Patients will only benefit from the interventional or surgical procedures when those revascularization measures that can cause more harm than good are avoided. In the new European Society of Cardiology and European Association for Cardio-Thoracic Surgery (ESC/EACTS) guidelines on myocardial revascularization some new aspects will be addressed.

11 Guideline [Diagnostics and therapy of chronic stable coronary artery disease : new guidelines of the European Society of Cardiology]. 2014

Athanasiadis, A / Sechtem, U / Anonymous1330798. ·Zentrum für Innere Medizin, Kardiologie, Robert-Bosch-Krankenhaus, Auerbachstr. 110, 70376, Stuttgart, Deutschland, anastasios.athanasiadis@rbk.de. · ·Herz · Pubmed #25384852.

ABSTRACT: The European Society of Cardiology (ESC) guidelines on the management of stable coronary artery disease published in 2013 give practical recommendations for diagnostics and therapy. The approach depends on the clinical picture and symptoms of the patient, the severity and extent of ischemia, the degree and location of coronary stenoses, additional cardiac findings and finally on non-cardiac comorbidities. The selection of suitable diagnostic tools is based on the tabulated pretest probability for the presence of coronary artery disease which plays an important and central role in the diagnostic algorithm. An invasive approach is recommended only in patients with severe angina, i.e. a Canadian Cardiovascular Society (CCS) angina grading scale of ≥ CCS3 or in patients who are at high risk for death or myocardial infarction based on the results of the test used for detection of ischemia. Detailed therapeutic recommendations are given for medicinal and interventional or surgical therapy. Medicinal therapy includes drugs both for relief of symptoms and prevention of cardiovascular events. Recommendations are also given for the use of new antianginal drugs. A PCI is only indicated in vessels causing ischemia which can be verified by using fractional flow reserve measurements. The indications for PCI now also include patients with a low SYNTAX score and multivessel disease or left main stenosis; however, the optimal strategy should be individually determined in heart team discussions.

12 Guideline Canadian Cardiovascular Society guidelines for the diagnosis and management of stable ischemic heart disease. 2014

Mancini, G B John / Gosselin, Gilbert / Chow, Benjamin / Kostuk, William / Stone, James / Yvorchuk, Kenneth J / Abramson, Beth L / Cartier, Raymond / Huckell, Victor / Tardif, Jean-Claude / Connelly, Kim / Ducas, John / Farkouh, Michael E / Gupta, Milan / Juneau, Martin / O'Neill, Blair / Raggi, Paolo / Teo, Koon / Verma, Subodh / Zimmermann, Rodney / Anonymous3070787. ·Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada. Electronic address: mancini@mail.ubc.ca. · Department of Medicine, Montreal Heart Institute, University of Montreal, Montréal, Québec, Canada. · Department of Medicine, Ottawa Heart Institute, Ottawa, Ontario, Canada. · Department of Medicine, University of Western Ontario, London, Ontario, Canada. · Department of Medicine, University of Calgary, Calgary, Alberta, Canada. · Vancouver Island Health Authority, Victoria, British Columbia, Canada. · Department of Medicine, St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada. · Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada. · Department of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada. · Department of Medicine, University Health Network Hospitals, University of Toronto, Toronto, Onario, Canada. · Department of Medicine, McMaster University, Hamilton, Ontario, Canada. · Department of Medicine, University of Alberta, Edmonton, Alberta, Canada. · Department of Medicine, Regina Qu'Appelle Health Region, University of Saskatchewan, Regina, Saskatchewan, Canada. · ·Can J Cardiol · Pubmed #25064578.

ABSTRACT: This overview provides a guideline for the management of stable ischemic heart disease. It represents the work of a primary and secondary panel of participants from across Canada who achieved consensus on behalf of the Canadian Cardiovascular Society. The suggestions and recommendations are intended to be of relevance to primary care and specialist physicians with an emphasis on rational deployment of diagnostic tests, expedited implementation of long- and short-term medical therapy, timely consideration of revascularization, and practical follow-up measures.

13 Guideline Cardiac risk factors: new cholesterol and blood pressure management guidelines. 2014

Anthony, David / George, Paul / Eaton, Charles B. ·Memorial Hospital of Rhode Island, 111 Brewster St., Pawtucket, RI 02903, USA. david_anthony@brown.edu · Warren Alpert Medical School of Brown University, 222 Richmond Street, Providence, RI 02903, USA. Paul-George@Brown.edu · Warren Alpert Medical School of Brown University, 222 Richmond Street, Providence, RI 02903, USA. Charles_Eaton@Brown.edu ·FP Essent · Pubmed #24936717.

ABSTRACT: The 2013 American College of Cardiology/American Heart Association cholesterol guidelines depart from low-density lipoprotein (LDL) treatment targets and recommend treating four specific patient groups with statins. Statins are the only cholesterol-lowering drugs with randomized trial evidence of benefit for preventing atherosclerotic cardiovascular disease (ASCVD). The groups are patients with clinical ASCVD; patients ages 40 to 75 years with diabetes and LDL of 70 to 189 mg/dL but no clinical ASCVD; patients 21 years or older with LDL levels of 190 mg/dL or higher; and patients ages 40 to 75 years with LDL of 70 to 189 mg/dL without clinical ASCVD or diabetes but with 10-year ASCVD risk of 7.5% or higher. Ten-year ASCVD risk may be calculated using the Pooled Cohort Equations. The Eighth Joint National Committee (JNC 8) guidelines for blood pressure management recommend a blood pressure goal of less than 140/90 mm Hg for all adults except those 60 years or older. For the latter group, the JNC 8 recommends a systolic blood pressure goal of less than 150 mm Hg. In another notable change from prior guidelines, the JNC 8 recommends relaxing the systolic blood pressure goal for patients with diabetes and chronic kidney disease to less than 140 mm Hg from less than 130 mm Hg.

14 Guideline Canadian Cardiovascular Society position statement on the management of thoracic aortic disease. 2014

Boodhwani, Munir / Andelfinger, Gregor / Leipsic, Jonathon / Lindsay, Thomas / McMurtry, M Sean / Therrien, Judith / Siu, Samuel C / Anonymous5200782. ·Division of Cardiac Surgery, University of Ottawa Heart Institute, Ottawa, Ontario, Canada. Electronic address: mboodhwani@ottawaheart.ca. · Department of Pediatrics, University of Montreal, Montreal, Québec, Canada. · Department of Radiology, University of British Colombia, Vancouver, British Colombia, Canada. · Division of Vascular Surgery, University Health Network, Toronto, Ontario, Canada. · Division of Cardiology, University of Alberta, Edmonton, Alberta, Canada. · Division of Cardiology, McGill University, Montreal, Québec, Canada. · Division of Cardiology, Western University, London, Ontario, Canada. · ·Can J Cardiol · Pubmed #24882528.

ABSTRACT: This Canadian Cardiovascular Society position statement aims to provide succinct perspectives on key issues in the management of thoracic aortic disease (TAD). This document is not a comprehensive overview of TAD and important elements of the epidemiology, presentation, diagnosis, and management of acute aortic syndromes are deliberately not discussed; readers are referred to the 2010 guidelines published by the American Heart Association, American College of Cardiology, American Association for Thoracic Surgery, and other stakeholders. Rather, this document is a practical guide for clinicians managing adult patients with TAD. Topics covered include size thresholds for surgical intervention, emerging therapies, imaging modalities, medical and lifestyle management, and genetics of TAD. The primary panel consisted of experts from a variety of disciplines that are essential for comprehensive management of TAD patients. The methodology involved a focused literature review with an emphasis on updates since 2010 and the use of Grading of Recommendations Assessment, Development, and Evaluation methodology to arrive at specific recommendations. The final document then underwent review by a secondary panel. This document aims to provide recommendations for most patients and situations. However, the ultimate judgement regarding the management of any individual patients should be made by their health care team.

15 Guideline SCAI/ACC/AHA Expert Consensus Document: 2014 update on percutaneous coronary intervention without on-site surgical backup. 2014

Dehmer, Gregory J / Blankenship, James C / Cilingiroglu, Mehmet / Dwyer, James G / Feldman, Dmitriy N / Gardner, Timothy J / Grines, Cindy L / Singh, Mandeep. · ·J Am Coll Cardiol · Pubmed #24651052.

ABSTRACT: -- No abstract --

16 Guideline Treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: synopsis of the 2013 American College of Cardiology/American Heart Association cholesterol guideline. 2014

Stone, Neil J / Robinson, Jennifer G / Lichtenstein, Alice H / Goff, David C / Lloyd-Jones, Donald M / Smith, Sidney C / Blum, Conrad / Schwartz, J Sanford / Anonymous5650778. · ·Ann Intern Med · Pubmed #24474185.

ABSTRACT: DESCRIPTION: In November 2013, the American College of Cardiology and American Heart Association (ACC/AHA) released a clinical practice guideline on the treatment of blood cholesterol to reduce cardiovascular risk in adults. This synopsis summarizes the major recommendations. METHODS: In 2008, the National Heart, Lung, and Blood Institute convened the Adult Treatment Panel (ATP) IV to update the 2001 ATP-III cholesterol guidelines using a rigorous process to systematically review randomized, controlled trials (RCTs) and meta-analyses of RCTs that examined cardiovascular outcomes. The panel commissioned independent systematic evidence reviews on low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol goals in secondary and primary prevention and the effect of lipid drugs on atherosclerotic cardiovascular disease events and adverse effects. In September 2013, the panel's draft recommendations were transitioned to the ACC/AHA. RECOMMENDATIONS: This synopsis summarizes key features of the guidelines in 8 areas: lifestyle, groups shown to benefit from statins, statin safety, decision making, estimation of cardiovascular disease risk, intensity of statin therapy, treatment targets, and monitoring of statin therapy.

17 Guideline ACCF/AHA/ASE/ASNC/HFSA/HRS/SCAI/SCCT/SCMR/STS 2013 multimodality appropriate use criteria for the detection and risk assessment of stable ischemic heart disease: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and Society of Thoracic Surgeons. 2014

Wolk, Michael J / Bailey, Steven R / Doherty, John U / Douglas, Pamela S / Hendel, Robert C / Kramer, Christopher M / Min, James K / Patel, Manesh R / Rosenbaum, Lisa / Shaw, Leslee J / Stainback, Raymond F / Allen, Joseph M / Anonymous3860772. · ·J Am Coll Cardiol · Pubmed #24355759.

ABSTRACT: The American College of Cardiology Foundation along with key specialty and subspecialty societies, conducted an appropriate use review of common clinical presentations for stable ischemic heart disease (SIHD) to consider use of stress testing and anatomic diagnostic procedures. This document reflects an updating of the prior Appropriate Use Criteria (AUC) published for radionuclide imaging (RNI), stress echocardiography (Echo), calcium scoring, coronary computed tomography angiography (CCTA), stress cardiac magnetic resonance (CMR), and invasive coronary angiography for SIHD. This is in keeping with the commitment to revise and refine the AUC on a frequent basis. A major innovation in this document is the rating of tests side by side for the same indication. The side-by-side rating removes any concerns about differences in indication or interpretation stemming from prior use of separate documents for each test. However, the ratings were explicitly not competitive rankings due to the limited availability of comparative evidence, patient variability, and range of capabilities available in any given local setting. The indications for this review are limited to the detection and risk assessment of SIHD and were drawn from common applications or anticipated uses, as well as from current clinical practice guidelines. Eighty clinical scenarios were developed by a writing committee and scored by a separate rating panel on a scale of 1 to 9, to designate Appropriate, May Be Appropriate, or Rarely Appropriate use following a modified Delphi process following the recently updated AUC development methodology. The use of some modalities of testing in the initial evaluation of patients with symptoms representing ischemic equivalents, newly diagnosed heart failure, arrhythmias, and syncope was generally found to be Appropriate or May Be Appropriate, except in cases where low pre-test probability or low risk limited the benefit of most testing except exercise electrocardiogram (ECG). Testing for the evaluation of new or worsening symptoms following a prior test or procedure was found to be Appropriate. In addition, testing was found to be Appropriate or May Be Appropriate for patients within 90 days of an abnormal or uncertain prior result. Pre-operative testing was rated Appropriate or May Be Appropriate only for patients who had poor functional capacity and were undergoing vascular or intermediate risk surgery with 1 or more clinical risk factors or an organ transplant. The exercise ECG was suggested as an Appropriate test for cardiac rehabilitation clearance or for exercise prescription purposes. Testing in asymptomatic patients was generally found to be Rarely Appropriate, except for calcium scoring and exercise testing in intermediate and high-risk individuals and either stress or anatomic imaging in higher-risk individuals, which were all rated as May Be Appropriate. All modalities of follow-up testing after a prior test or percutaneous coronary intervention (PCI) within 2 years and within 5 years after coronary artery bypass graft (CABG) in the absence of new symptoms were rated Rarely Appropriate. Pre-operative testing for patients with good functional capacity, prior normal testing within 1 year, or prior to low-risk surgery also were found to be Rarely Appropriate. Imaging for an exercise prescription or prior to the initiation of cardiac rehabilitation was Rarely Appropriate except for cardiac rehabilitation clearance for heart failure patients.

18 Guideline 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014

Stone, Neil J / Robinson, Jennifer G / Lichtenstein, Alice H / Bairey Merz, C Noel / Blum, Conrad B / Eckel, Robert H / Goldberg, Anne C / Gordon, David / Levy, Daniel / Lloyd-Jones, Donald M / McBride, Patrick / Schwartz, J Sanford / Shero, Susan T / Smith, Sidney C / Watson, Karol / Wilson, Peter W F / Anonymous1000785. · ·J Am Coll Cardiol · Pubmed #24239923.

ABSTRACT: -- No abstract --

19 Guideline 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. 2014

Jensen, Michael D / Ryan, Donna H / Apovian, Caroline M / Ard, Jamy D / Comuzzie, Anthony G / Donato, Karen A / Hu, Frank B / Hubbard, Van S / Jakicic, John M / Kushner, Robert F / Loria, Catherine M / Millen, Barbara E / Nonas, Cathy A / Pi-Sunyer, F Xavier / Stevens, June / Stevens, Victor J / Wadden, Thomas A / Wolfe, Bruce M / Yanovski, Susan Z / Anonymous960785 / Anonymous970785. · ·J Am Coll Cardiol · Pubmed #24239920.

ABSTRACT: -- No abstract --

20 Guideline Drug-coated balloon treatment of coronary artery disease: a position paper of the Italian Society of Interventional Cardiology. 2014

Cortese, Bernardo / Berti, Sergio / Biondi-Zoccai, Giuseppe / Colombo, Antonio / Limbruno, Ugo / Bedogni, Francesco / Cremonesi, Alberto / Silva, Pedro Leon / Sgueglia, Gregory A / Anonymous5780772. ·Interventional Cardiology, A.O. Fatebenefratelli Milano, Italy. · ·Catheter Cardiovasc Interv · Pubmed #23934956.

ABSTRACT: Drug-coated balloons are a new tool for the treatment of patients with coronary artery disease. The main feature of this technology is a rapid and homogenous transfer of an antiproliferative drug (paclitaxel) to the vessel wall just at the time of balloon inflation, when neointimal proliferation, in response to angioplasty, is the highest. Moreover, drug-coated balloons share adjuntive advantages over stents: the absence of permanent scaffold and polymer, the respect of the original coronary anatomy, and limited inflammatory stimuli, thereby allowing for short-term dual antiplatelet therapy. To this day, a lot of devices are available in the market, with limited scientific data for the vast majority of them. Thus, the Italian scientific society of interventional cardiologists GISE decided to coordinate the efforts of a group of reknown experts on the field, in order to obtain a Position Paper on the correct use of drug-coated balloons in all the settings of coronary artery disease, giving a class of indication to each one, based on the clinical evidence. This Position Paper represents a quick reference for operators, investigators, and manufactures to promote the understanding and the correct use of the drug-coated balloon technology in everyday clinical practice.

21 Guideline Secondary prevention of atherosclerotic cardiovascular disease in older adults: a scientific statement from the American Heart Association. 2013

Fleg, Jerome L / Forman, Daniel E / Berra, Kathy / Bittner, Vera / Blumenthal, James A / Chen, Michael A / Cheng, Susan / Kitzman, Dalane W / Maurer, Mathew S / Rich, Michael W / Shen, Win-Kuang / Williams, Mark A / Zieman, Susan J / Anonymous5180764. · ·Circulation · Pubmed #24166575.

ABSTRACT: -- No abstract --

22 Guideline Optimizing chronic disease management in the community (outpatient) setting (OCDM): an evidentiary framework. 2013

Anonymous4730761. · ·Ont Health Technol Assess Ser · Pubmed #24143159.

ABSTRACT: -- No abstract --

23 Guideline [SICI-GISE position paper on drug-coated balloon use in the coronary district]. 2013

Cortese, Bernardo / Sgueglia, Gregory A / Berti, Sergio / Biondi-Zoccai, Giuseppe / Colombo, Antonio / Limbruno, Ugo / Bedogni, Francesco / Cremonesi, Alberto / Anonymous780761. · ·G Ital Cardiol (Rome) · Pubmed #24121894.

ABSTRACT: Drug-coated balloons are a new tool for the treatment of patients with coronary artery disease. The main feature of this technology is a rapid and homogeneous transfer of an antiproliferative drug (paclitaxel) to the vessel wall just at the time of balloon inflation, when neointimal proliferation, in response to angioplasty, is the highest. Moreover, drug-coated balloons share adjunctive advantages over stents: the absence of permanent scaffold and polymer, the respect of the original coronary anatomy, and limited inflammatory stimuli, thereby allowing for short-term dual antiplatelet therapy. At present, a variety of devices are available in the market, with limited scientific data for the vast majority of them. Thus, the Italian Society of Interventional Cardiology (SICI-GISE) decided to coordinate the efforts of a group of renowned experts in this field, in order to produce a position paper on the correct use of drug-coated balloons in all settings of coronary artery disease, giving a class of indication to each one, based on clinical evidence. This position paper represents a quick reference for operators, investigators and manufacturers to promote the understanding and the correct use of the drug-coated balloon technology in everyday clinical practice.

24 Guideline Screening for the presence of coronary artery disease. 2013

Anonymous5190759 / Poirier, Paul / Dufour, Robert / Carpentier, André / Larose, Éric. · ·Can J Diabetes · Pubmed #24070928.

ABSTRACT: -- No abstract --

25 Guideline 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. 2013

Anonymous3540760 / Montalescot, Gilles / Sechtem, Udo / Achenbach, Stephan / Andreotti, Felicita / Arden, Chris / Budaj, Andrzej / Bugiardini, Raffaele / Crea, Filippo / Cuisset, Thomas / Di Mario, Carlo / Ferreira, J Rafael / Gersh, Bernard J / Gitt, Anselm K / Hulot, Jean-Sebastien / Marx, Nikolaus / Opie, Lionel H / Pfisterer, Matthias / Prescott, Eva / Ruschitzka, Frank / Sabaté, Manel / Senior, Roxy / Taggart, David Paul / van der Wall, Ernst E / Vrints, Christiaan J M / Anonymous3550760 / Zamorano, Jose Luis / Achenbach, Stephan / Baumgartner, Helmut / Bax, Jeroen J / Bueno, Héctor / Dean, Veronica / Deaton, Christi / Erol, Cetin / Fagard, Robert / Ferrari, Roberto / Hasdai, David / Hoes, Arno W / Kirchhof, Paulus / Knuuti, Juhani / Kolh, Philippe / Lancellotti, Patrizio / Linhart, Ales / Nihoyannopoulos, Petros / Piepoli, Massimo F / Ponikowski, Piotr / Sirnes, Per Anton / Tamargo, Juan Luis / Tendera, Michal / Torbicki, Adam / Wijns, William / Windecker, Stephan / Anonymous3560760 / Knuuti, Juhani / Valgimigli, Marco / Bueno, Héctor / Claeys, Marc J / Donner-Banzhoff, Norbert / Erol, Cetin / Frank, Herbert / Funck-Brentano, Christian / Gaemperli, Oliver / Gonzalez-Juanatey, José R / Hamilos, Michalis / Hasdai, David / Husted, Steen / James, Stefan K / Kervinen, Kari / Kolh, Philippe / Kristensen, Steen Dalby / Lancellotti, Patrizio / Maggioni, Aldo Pietro / Piepoli, Massimo F / Pries, Axel R / Romeo, Francesco / Rydén, Lars / Simoons, Maarten L / Sirnes, Per Anton / Steg, Ph Gabriel / Timmis, Adam / Wijns, William / Windecker, Stephan / Yildirir, Aylin / Zamorano, Jose Luis. ·The disclosure forms of the authors and reviewers are available on the ESC website www.escardio.org/guidelines. · ·Eur Heart J · Pubmed #23996286.

ABSTRACT: -- No abstract --

Next